A phase 1 study of ASTX727 plus talazoparib in patients with triple-negative or hormone resistant/HER2-negative metastatic breast cancer. - Miller KD; Thomas A; Althouse S; Zang Y; Conder E; Burgos R; Schneider BP; Ballinger T; Douglas E; Ansley K; Jang HJ; Chung W; et al. (Cancer, 2026)